Pharmacological profiling of the largest collection of enantiopure synthetic cannabinoid receptor agonists revealed structure-activity relationships, some compounds with limited harm potential, and significant neurotoxicity for representative SCRAs.
Read this if you work in forensic science, drug policy, or pharmacology of synthetic cannabinoids.
Largest libraryMost diverse collection of enantiopure SCRAs synthesized and pharmacologically characterized to date
What the researchers found
The largest and most diverse collection of enantiopure SCRAs was synthesized and characterized. Novel SCRAs with (R) configuration were tested for the first time. Systematic profiling identified SAR and selectivity trends, including some compounds with incipient CB2 selectivity. Several emerging SCRAs showed lower potencies/efficacies, suggesting limited harm potential. However, representative SCRAs demonstrated significant neurotoxicity on mouse primary neuronal cells. The library is intended as a shared resource for studying SCRA effects.
Why it matters
New synthetic cannabinoids appear constantly, often before any pharmacological data exists. This library provides reference data for forensic chemists, toxicologists, and regulators to assess the harm potential of novel compounds as they emerge.
The numbers in context
- Largest and most diverse SCRA collection published to date
- 32 novel SCRAs with (R) configuration first reported
- Both binding and functional pharmacological data
- SAR and SSR trends identified
- Some compounds show CB2 subtype selectivity
- Significant neurotoxicity confirmed for representative SCRAs
How the study worked
Synthesis of enantiopure SCRA library. Binding and functional pharmacological evaluation at CB1 and CB2 receptors. Neurotoxicity assessment on mouse primary neuronal cells. SAR and selectivity analysis.
Who was studied
In vitro pharmacological characterization (no human subjects)
What this study cannot tell us
In vitro pharmacology may not predict all in vivo effects. The drug market evolves faster than any single study can characterize. Neurotoxicity assessed on a limited number of representative compounds.
How to read the evidence
Comprehensive pharmacological characterization study. Strong methodology providing reference data for the field.
When this study was published
Published in 2023. Provides essential reference data as new SCRAs continue to emerge.
The bigger picture
The synthetic cannabinoid problem requires systematic pharmacological intelligence. This kind of preemptive characterization helps predict which new compounds will be most dangerous before they cause harm.
Questions still open
- Can this library predict the next dangerous synthetic cannabinoid to emerge?
- Do the CB2-selective compounds have legitimate therapeutic potential?
- How quickly can new emerging SCRAs be added to this pharmacological database?
Read the original research
Pharmacological insights emerging from the characterization of a large collection of synthetic cannabinoid receptor agonists designer drugs.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 164, 114934
Citation
Gioé-Gallo, Claudia; Ortigueira, Sandra; Brea, José; Raïch, Iu; Azuaje, Jhonny; Paleo, M Rita; Majellaro, Maria; Loza, María Isabel; Salas, Cristian O; García-Mera, Xerardo; Navarro, Gemma; Sotelo, Eddy. (2023). Pharmacological insights emerging from the characterization of a large collection of synthetic cannabinoid receptor agonists designer drugs.. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 164, 114934. https://doi.org/10.1016/j.biopha.2023.114934